284 related articles for article (PubMed ID: 21134983)
1. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
[TBL] [Abstract][Full Text] [Related]
2. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
[TBL] [Abstract][Full Text] [Related]
5. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
6. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
[TBL] [Abstract][Full Text] [Related]
7. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
8. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
10. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Shah NP; Nicoll JM; Nagar B; Gorre ME; Paquette RL; Kuriyan J; Sawyers CL
Cancer Cell; 2002 Aug; 2(2):117-25. PubMed ID: 12204532
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
12. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Jabbour E; Kantarjian H
Am J Hematol; 2012 Nov; 87(11):1037-45. PubMed ID: 23090888
[TBL] [Abstract][Full Text] [Related]
14. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
15. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
16. A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
Sakai K; Ishikawa Y; Mori Y; Kobayashi M; Iriyama C; Ozawa Y; Suzuki T; Minami Y; Ishikawa K; Kaneda N; Naoe T; Kiyoi H
Int J Hematol; 2011 Feb; 93(2):237-242. PubMed ID: 21264552
[TBL] [Abstract][Full Text] [Related]
17. Mutant BCR-ABL clones in chronic myeloid leukemia.
Mathisen MS; Kantarjian HM; Cortes J; Jabbour E
Haematologica; 2011 Mar; 96(3):347-9. PubMed ID: 21357713
[No Abstract] [Full Text] [Related]
18. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Parker WT; Lawrence RM; Ho M; Irwin DL; Scott HS; Hughes TP; Branford S
J Clin Oncol; 2011 Nov; 29(32):4250-9. PubMed ID: 21990409
[TBL] [Abstract][Full Text] [Related]
19. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
[TBL] [Abstract][Full Text] [Related]
20. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Shah NP; Skaggs BJ; Branford S; Hughes TP; Nicoll JM; Paquette RL; Sawyers CL
J Clin Invest; 2007 Sep; 117(9):2562-9. PubMed ID: 17710227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]